Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights

SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. AstraZeneca PLC, a leader in the field, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses have shown a steady upward trend, peaking at approximately $18 billion in 2022, reflecting a strategic investment in market expansion and operational efficiency.

In contrast, ImmunityBio, Inc., a burgeoning player, has maintained a more conservative approach. Their SG&A expenses, while growing, remain a fraction of AstraZeneca's, with a peak of around $130 million in 2023. This disparity highlights the differing scales and strategies of these companies. AstraZeneca's expenses are nearly 140 times greater than ImmunityBio's, underscoring its expansive market reach and established presence.

This comparison offers valuable insights into the financial dynamics and strategic priorities of these pharmaceutical companies.